梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2009年年度报告「NYSE」.pdf

1、v UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2

2、009 OR?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)O F THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number:0-16174 OR?SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company re

3、port:TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of Registrant as specified in its charter)Not Applicable (Translation of Registrants name into English)ISRAEL (Jurisdiction of incorporation or organization)5 Basel Street P.O.Box 3190 Petach Tikva 49131,Israel (Address of principal executive o

4、ffices)Eyal Desheh Chief Financial Officer Teva Pharmaceutical Industries Limited 5 Basel Street P.O.Box 3190 Petach Tikva 49131,Israel Tel:972-3-914-8171 Fax:972-3-914-8605 (Name,telephone,e-mail and/or facsimile number and address of Company contact person)Securities registered or to be registered

5、 pursuant to Section 12(b)of the Act.Title of each class Name of each exchange on which registered American Depositary Shares,each representing one Ordinary Share The Nasdaq Stock Market LLC Securities registered or to be registered pursuant to Section 12(g)of the Act.None (Title of Class)Securities

6、 for which there is a reporting obligation pursuant to Section 15(d)of the Act.None (Title of Class)Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.923,400,051 Ordinary Shares 719,745,494 A